



# ESMO Preceptorship on Prostate Cancer

## PROGRAMME

**ESMO  
PRECEPTORSHIP**

**LUGANO SWITZERLAND  
18-19 DECEMBER 2024**

**Co-Chairs**

Karim Fizazi, France

Silke Gillissen, Switzerland

# ESMO PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,  
therapeutic targets and future perspectives

Lugano, Switzerland  
18-19 December 2024

---

**CO-CHAIRS** Karim Fizazi, France  
Silke Gillessen, Switzerland

**SPEAKERS** Giulia Baciarello, Italy  
Elena Castro, Spain  
Eva Compérat, Austria  
Ken Herrmann, Germany  
Jochen Walz, France  
Thomas Zilli, Switzerland

---

## LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

---

## ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](https://www.esmo.org).

---

## ACKNOWLEDGEMENTS

This event has been supported by funding from the following companies

**Johnson & Johnson**

Supported by a grant from Pfizer Inc.

---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 18 December 2024

<b>09:00-09:10</b> 10'	<b>Opening and welcome</b>	
10'	Welcome from ESMO - Objectives and scientific introduction	Karim Fizazi, FR Silke Gillissen, CH
<b>09:10-10:50</b> 100'	<b>SESSION 1</b> <b>Screening, diagnosis, staging and localised prostate cancer</b>	<b>Chairs:</b> Eva Compérat, AT Jochen Walz, FR
15'	PSA screening and diagnosis	Jochen Walz, FR
10'	Staging	Jochen Walz, FR
15'	Pathological diagnosis for the clinician (including variants of PCa)	Eva Compérat, AT
15'	Treatment of localised prostate cancer according to risk category	Jochen Walz, FR
15'	Radiotherapeutic approaches for localised prostate cancer	Thomas Zilli, CH
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
<b>10:50-11:20</b>	<b>Coffee break</b>	
<b>11:20-12:45</b> 85'	<b>SESSION 2</b> <b>Biochemical relapse</b>	<b>Chairs:</b> Giulia Baciarello, IT Thomas Zilli, CH
15'	Biochemical relapse: Definition and diagnostic algorithm	Giulia Baciarello, IT
20'	Rising PSA after radical local treatment: Prognosis, indications for salvage local treatments, salvage vs adjuvant treatments	Thomas Zilli, CH
20'	Use of early vs deferred systemic treatments in high-risk localized CaP and biochemical failures	Karim Fizazi, FR
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
<b>12:45-13:45</b>	<b>Lunch</b>	
<b>13:45-15:25</b> 100'	<b>SESSION 3</b> <b>Systemic treatment options and molecular characterisation</b>	<b>Chairs:</b> Elena Castro, ES Jochen Walz, FR
20'	ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities	Silke Gillissen, CH
20'	Chemotherapy (taxanes and platins) and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities	Elena Castro, ES
15'	Bone health agents, mechanism of action, efficacy and toxicities	Giulia Baciarello, IT
15'	Molecular characterisation: Germline and somatic testing	Elena Castro, ES
15'	Q&A	All

15'	Participants clinical case discussion (1x15')	Faculty
<b>15:25-15:55</b>	<b>Coffee break</b>	
<b>15:55-17:25 90'</b>	<b>SESSION 4 Castration-sensitive metastatic prostate cancer</b>	<b>Chairs: Karim Fizazi, FR Silke Gillessen, CH</b>
20'	Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Silke Gillessen, CH
15'	Triplet and quadruplet options (mCSPC)	Karim Fizazi, FR
10'	Monitoring of mCSPC	Ken Herrmann, DE
15'	Oligo-metastatic disease: What treatment?	Thomas Zilli, CH
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
<b>19:30</b>	<b>Networking Dinner</b>	

## Thursday, 19 December 2024

<b>09:00-10:45 105'</b>	<b>SESSION 5 Non metastatic and metastatic castration-resistant disease</b>	<b>Chairs: Giulia Baciarello, IT Elena Castro, ES</b>
20'	Non metastatic CRPC: Current treatment	Giulia Baciarello, IT
20'	Metastatic CRPC: Current treatment	Silke Gillessen, CH
20'	PSMA-based therapies	Ken Herrmann, DE
15'	Q&A	All
30'	Participants clinical case discussion (2x15')	Faculty
<b>10:45-11:15</b>	<b>Coffee break</b>	
<b>11:15-12:20 65'</b>	<b>SESSION 6 Metastatic castration-resistant disease</b>	<b>Chairs: Karim Fizazi, FR Silke Gillessen, CH</b>
15'	Treatment in frail patients with mCRPC	Elena Castro, ES
20'	Experimental treatments for mCRPC	Karim Fizazi, FR
15'	Q&A	All
15'	Participants clinical case discussion (1x15')	Faculty
<b>12:20-12:30 10'</b>	<b>Conclusion and farewell</b>	<b>Karim Fizazi, FR Silke Gillessen, CH</b>
<b>12:30-13:30</b>	<b>Lunch</b>	

**Note:** Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion